Polaryx Therapeutics is progressing its lead candidate, PLX-200, through regulatory milestones with plans to initiate a pivotal Phase 2 proof-of-concept basket trial in H2 2026 for multiple rare pediatric lysosomal storage disorders (LSDs). The latest quarterly filing confirms ongoing operational and financial status, highlighting the company’s reliance on PLX-200’s success. Polaryx’s strategy leverages a repurposed drug via the 505(b)(2) pathway combined with a proprietary pediatric oral formulation. While the clinical and regulatory paths have encouraging designations, execution risks remain significant, as does the need for capital to sustain development.